Pluvicto for Prostate Cancer: PSMA PET, Eligibility and China Access
Learn who may qualify for lutetium-177 PSMA radioligand therapy, what tests matter, how it compares with other treatments, and what must be verified before travel to China.
Pluvicto at a glance
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a PSMA-targeted radioligand medicine for selected people with metastatic prostate cancer. It is not a general cure, an alternative to standard treatment for low-risk localized cancer, or a therapy that can be booked in China based on a search result.
Clinical information reviewed: 21 November 2026. ParkMega helps patients organize a second opinion and request written information from a hospital; your treating oncologist decides whether the therapy is appropriate. Regulatory approval in one country does not establish availability for international patients in China.
Disease stage, prior treatment, lab results and overall health.
A specialist interprets PSMA expression and the imaging workup.
Drug access, international-patient acceptance and a written estimate must be confirmed.
Quick answer: who can be considered for Pluvicto?
The US FDA expanded the mCRPC indication on 28 March 2025 to include certain PSMA-positive metastatic castration-resistant patients after an androgen-receptor pathway inhibitor who can appropriately delay taxane chemotherapy. The FDA also approved a separate combination indication on 31 July 2026 with an androgen-receptor pathway inhibitor for certain PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive patients. These are different clinical settings; eligibility depends on the precise authorization and specialist assessment.
FDA indications describe US regulatory decisions, not a patient-specific prescription and not a Chinese import, license, supply or referral guarantee.
PSMA PET, pathology and tests needed before a review
- Pathology report confirming prostate cancer and, where relevant, Gleason score / Grade Group.
- Current clinical stage, metastatic sites, recent PSA and testosterone data.
- PSMA PET/CT report with imaging files (DICOM when available), plus relevant CT/MRI or bone imaging.
- A dated record of androgen-deprivation therapy, ARPIs, chemotherapy, radiotherapy and other treatments, including responses and adverse effects.
- Current blood count, renal and liver function tests, comorbidities and performance status as requested by the treating team.
A nuclear-medicine and oncology team interprets PSMA expression, disease pattern, marrow and kidney risks, and whether other treatments are more suitable. A single elevated PSA is not sufficient to decide on Pluvicto.
How radioligand therapy works and what to expect
Pluvicto carries lutetium-177 to cells expressing prostate-specific membrane antigen (PSMA). Unlike an external-beam radiation course, the medicine circulates through the body and delivers radiation to PSMA-expressing sites. Treatment planning requires nuclear-medicine expertise, radiation protection procedures and a monitoring program.
Reported risks include fatigue, dry mouth, nausea, reduced blood counts and kidney-related concerns. They may affect dose timing, supportive care and whether treatment should continue. Discuss radiation-safety instructions, contacts with family members and the monitoring schedule with the actual treating center; individual instructions should come from its clinical team.
Pluvicto versus other prostate cancer treatments
- Early or localized prostate cancer: active surveillance, surgery, radiotherapy and other standard options are assessed by Grade Group, PSA, stage and health. Pluvicto is not a substitute for those decisions.
- Metastatic hormone-sensitive disease: androgen-deprivation and pathway-targeted systemic therapy form the basis of many plans; the 2026 US combination approval must be read in its exact indication.
- Metastatic castration-resistant disease: options may include taxanes, ARPIs, PARP inhibitors for some biomarker-defined patients, radiopharmaceuticals or clinical trials. Prior treatment and tumor biology determine sequencing.
Outcomes, tolerability and quality of life should be compared for the same disease setting; general claims that one treatment is ‘best’ are misleading.
Is Pluvicto available in China to an international patient?
Not confirmed by ParkMega. Before recommending travel, request a written response from the named Chinese institution confirming (1) legal access to the specified product and indication, (2) its nuclear-medicine/radiopharmacy capacity, (3) acceptance of an overseas patient, (4) required PSMA imaging and laboratory workup, and (5) a case-specific estimate. A hospital’s ability to perform radioligand therapy does not prove access to this brand or its newest US indication.
If the requested pathway is unavailable or inappropriate, ask for a realistic second opinion on standard care at home or another qualified center rather than traveling for the drug name alone.
How much can Pluvicto and the workup cost in China?
There is no verified all-inclusive China price or booking offer on this page. A credible estimate should separate consultation, PSMA PET/CT, any repeated diagnostics, product and administration charges if available, blood monitoring, management of toxicity, hospital or outpatient fees, interpretation and travel. A price quoted elsewhere is not transferable to another hospital or patient.
Start with the Cancer Treatment Cost in China guide and request an itemized written estimate after your medical records are reviewed.
What to send for a second-opinion request
- A concise diagnosis and timeline, including date and location of pathology.
- Previous treatments and their start/stop dates.
- PSA history, pathology, radiology and PSMA PET report if performed.
- Current blood tests and a clear question: eligibility, alternatives, cost or availability.
Do not upload sensitive medical records into a public comment form. First request instructions for the clinic-approved secure submission channel. Ask ParkMega about the case-review process. A review request does not guarantee treatment, timing or results.
Frequently asked questions
Is Pluvicto chemotherapy?
No. It is PSMA-targeted radioligand therapy. It has a different mechanism and needs specialist assessment and radiation-safety arrangements.
Do I need PSMA PET/CT?
PSMA-positive disease must be demonstrated with the appropriate imaging and interpretation under the relevant clinical criteria. The treating specialist decides what imaging is needed.
Can Pluvicto cure early-stage prostate cancer?
It is not a standard replacement for localized-prostate-cancer care. Management at earlier stages should be discussed with a urologic oncology team.
Does FDA approval mean I can receive it in Guangzhou or Shanghai?
No. Chinese regulatory status, hospital access, treatment logistics and acceptance of international patients must be checked independently and in writing.
Can I compare Pluvicto with proton therapy or HIFU?
Yes, but only in the context of diagnosis, stage and treatment intent. Localized treatment and systemic radioligand treatment address different clinical situations.
Related ParkMega guides
- Prostate Cancer Treatment in China — surgery, radiation, HIFU and stage-based decisions.
- New Cancer Treatments in China — approval versus clinical trial.
- Cancer Hospitals in China — how to assess specialist departments.
- Русская статья о лечении рака простаты в Китае.
- Pluvicto и лютеций-177 — русский материал.
Medical sources and verification
- FDA — 28 March 2025, mCRPC indication expansion.
- FDA — 31 July 2026, combination indication.
- National Cancer Institute — radiopharmaceutical therapy.
Educational content, not medical advice or a promise of Chinese hospital availability. Last medically reviewed 21 November 2026.
Request a case and hospital-availability review
If you have biopsy, PSA history and PSMA PET/CT reports, contact ParkMega for the next steps. Ask first about an appropriate secure channel for medical records. Submitting an inquiry does not guarantee access to Pluvicto, treatment timing or results.
Educational information only; there is no confirmed China availability or fixed treatment price.